罗氟司特乳膏治疗银屑病的效果怎么样

罗氟司特乳膏治疗银屑病的效果显著，是是有效的局部皮质类固醇的替代品，可用于治疗任何严重的斑块型银屑病，且其使用时间没有任何限制。 Roflumilast cream can relieve patients' itching symptoms and improve their skin condition. Roflumilast cream is a next-generation phosphodiesterase type 4 (PDE4) inhibitor. PDE4 is an intracellular protease that increases the production of pro-inflammatory mediators and decreases the production of anti-inflammatory mediators and is associated with a wide range of inflammatory diseases. Roflumilast has been shown to be safe and effective in multiple clinical trials, improving disease clearance in hard-to-treat areas such as knees and elbows, as well as sensitive areas such as the face, genitals, and intertriginous areas.

In a phase 2b double-blind trial, adults with plaque psoriasis were randomly assigned in a 1:1:1 ratio to receive 0.3% roflumilast cream, 0.15% roflumilast cream, or vehicle (placebo) cream once daily for 12 weeks.

试验结果显示在331名接受随机分组的患者中，109名患者被分配使用0.3%罗氟司特乳膏，113名患者被指定使用0.15%罗氟司特乳膏，109名被指定使用载体乳膏。在第6周，罗氟司特0.3%组28%的患者、罗氟司特0.15%组23%的患者和赋形剂组8%的患者观察到IGA评分显示清晰或几乎清晰（分别与0.3%和0.15%的赋形剂相比，P＜0.001和P＝0.004）。

结论：罗氟司特乳膏每天给药一次，用于银屑病的患处，在6周时使其达到透明或几乎透明的状态方面优于载体乳膏。

Common side effects of Roflumilast cream include headache, anxiety, weight loss, loss of appetite, insomnia (difficulty sleeping), depression, suicidal thoughts or other mood changes, diarrhea, nausea (feeling uncomfortable), abdominal pain (stomach pain), etc. Usually the manifestations of side effects will vary depending on the patient's constitution and condition. It is important to note that roflumilast cream is for topical use only and is not intended for eye, oral, or intravaginal use.

Recommended related articles:

References

Lebwohl MG, Papp KA, Stein Gold L, Gooderham MJ, Kircik LH, Draelos ZD, Kempers SE, Zirwas M, Smith K, Osborne DW, Trotman ML, Navale L, Merritt C, Berk DR, Welgus H; ARQ-151 201 Study Investigators. Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239. doi: 10.1056/NEJMoa2000073. PMID: 32668113.